BEIJING, Feb. 26, 2026 — InnoCare Pharma (HKEX: 09969), a prominent biopharmaceutical firm specializing in therapies for cancer and autoimmune conditions, today disclosed significant advancements in its clinical development, notably the successful completion of patient enrollment for several Phase III registrational trials.
The company has finalized patient enrollment for a Phase III registrational clinical trial evaluating its BCL2 inhibitor mesutoclax (ICP-248) when combined with the BTK inhibitor orelabrutinib, intended for patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Mesutoclax represents a new, highly selective oral BCL2 inhibitor. BCL2, a crucial regulatory protein within the apoptosis pathway, is linked to the progression of various hematologic cancers when abnormally expressed. Mesutoclax demonstrates anti-tumor effects by specifically targeting and inhibiting BCL2, thereby re-establishing normal apoptosis in cancerous cells. The fixed-duration regimen of mesutoclax combined with orelabrutinib is anticipated to achieve more profound remission in treatment-naïve CLL/SLL patients lacking drug-resistant mutations, offering the prospect of a clinical cure for this patient population.
Furthermore, InnoCare has expedited the clinical advancement of two innovative TYK2 inhibitors. The company recently concluded patient enrollment for the Phase III registrational trial of soficitinib (ICP-332) targeting moderate to severe atopic dermatitis (AD), as well as for the Phase III registrational trial of ICP-488 for psoriasis treatment.
These significant achievements signify a vital progression in addressing the substantial unmet medical needs in atopic dermatitis with soficitinib and in psoriasis with ICP-488.
Concurrently, InnoCare has also finalized patient enrollment for the Phase II clinical trial of soficitinib, which is being investigated for the treatment of vitiligo.
Soficitinib is a powerful and selective TYK2 inhibitor under development for managing a range of T-cell related autoimmune conditions. Its current indications in development are strategically aimed at the extensive dermatology market, encompassing AD, vitiligo, prurigo nodularis, CSU, and psoriasis.
ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor. Through its binding to the JH2 domain, ICP-488 obstructs the signal transduction pathways of IL-23, IL-12, type 1 IFN, and other inflammatory cytokines, consequently suppressing the pathological mechanisms of autoimmune and inflammatory diseases.
About InnoCare
InnoCare is a biopharmaceutical company at the commercial stage dedicated to the discovery, development, and commercialization of first-in-class and/or best-in-class medications for addressing cancers and autoimmune diseases with significant unmet medical needs both in China and globally. InnoCare maintains offices in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report includes certain forward-looking statements. Apart from factual declarations, all other statements should be considered forward-looking, pertaining to the intentions, plans, beliefs, or expectations of our company or management regarding future events. These statements are assumptions and estimations formulated by our management, drawing upon their experience and understanding of historical patterns, current circumstances, anticipated future growth, and other pertinent factors. Such forward-looking statements do not assure future outcomes, and actual results, developments, and business choices might diverge from the projections within these statements. Our forward-looking statements are also subject to numerous risks and uncertainties that could influence our short-term and long-term performance.
| Contact Information | |
| For Media Inquiries | For Investors |
| Chunhua Lu 86-10-66609879 |
86-10-66609999 |
